Company profile
UK company 12082645, incorporated on 3 July 2019.
ERROR: The requested URL could not be retrieved
Myricx Pharma Limited is a UK company with status Active founded in 2019 based in London.
Company number 12082645
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
CS01 | Transaction MzUzMTI0OTgzOGFkaXF6a2N4
Published 08 Jul 2026 10:13
CH01 | Transaction MzUzMTAwNDc5M2FkaXF6a2N4
Published 07 Jul 2026 13:20
Last confirmation statement made up date
Last accounts made up date
SH01 | Transaction MzQ0ODU1MTEwNGFkaXF6a2N4 | Paper/PDF filed
Published 19 Jun 2026 22:39
AP01 | Transaction MzI0ODcwNDExNWFkaXF6a2N4 | Paper/PDF filed
Published 01 Jul 2026 22:44
Company registered at Companies House
Translating world leading research in NMT into novel medicines Myricx Pharma ("Myricx") is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across viral and other diseases. The Company is based on novel discoveries from the research laboratories of its co-founders, Prof Ed Tate, Dr Roberto Solari and Dr Andrew Bell. The research teams identified that inhibition of NMT, an enzyme involved in myristoylation of certain proteins, results in specific cancer cell killing via an unexpected and unique mechanism. This breakthrough discovery reveals that NMT inhibitors are proving to be highly effective in the treatment of MYC-driven cancer models. Until now MYC was considered to be undruggable. Myricx is now prioritising the development of potent small-molecule inhibitors with the aim of building a proprietary pipeline of targeted cancer therapies.
Leading the translation of NMT science into promising new precision medicines Myristoylation, is a lipid modification to a specific group of proteins that allows them to interact with other proteins or membranes. It is catalysed by the enzyme N-myristoyltransferase (NMT) which introduces irreversible changes to human proteins and is known to be involved in a range of diseases including cancer, inflammatory conditions, epilepsy and Alzheimer's disease. Myricx is based on over 15 years of research focused on the function of NMT and on gaining a deep understanding of its enzymology and structure, as well as biology. Myristoylation plays vital roles in protein-protein interactions, targeting proteins to cytoplasmic and plasma membranes, and regulating cellular signalling pathways in several biological processes.
